B. Ha

发表

Long-term body composition changes in antiretroviral-treated HIV-infected individuals

A. Collier, D. Kitch, T. Brown, 2016, AIDS.

Antiretroviral Exposure and Lymphocyte mtDNA Content Among Uninfected Infants of HIV-1-Infected Women

G. Aldrovandi, B. Ha, J. Walter, 2009, Pediatrics.

Comparison of Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir and Tenofovir: The Nucleoside Inflammation, Coagulation and Endothelial Function (Nice) Study

C. Fichtenbaum, P. Sax, B. Taiwo, 2014, Antiviral therapy.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

D. Katzenstein, K. Tashima, P. Sax, 2011, The Journal of infectious diseases.

Impact of Switch to Fosamprenavir and Addition of Lovaza ® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

B. Ha, H. Khanlou, L. Ross, 2012 .

Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

B. Ha, D. Berger, W. Towner, 2008, HIV clinical trials.

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

D. Kitch, T. Brown, G. McComsey, 2017, Journal of Antimicrobial Chemotherapy.

Interlaboratory Measurement Differences in Intracellular Carbovir Triphosphate Concentrations in HIV‐Infected Patients: Sources of Variability in Processing, Shipping, and Quantitation

R. Haubrich, D. Richman, Sonia Jain, 2010, Journal of clinical pharmacology.

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

B. Ha, E. Dejesus, C. Small, 2013, BMC Infectious Diseases.

Virologic Response and Safety of the Abacavir/Lamivudine Fixed-Dose Formulation as Part of Highly Active Antiretroviral Therapy: Analyses of Six Clinical Studies

B. Ha, L. Dix, K. Pappa, 2009, HIV clinical trials.

Simplified Maintenance Therapy With Abacavir/Lamivudine and Atazanavir After Discontinuation of Ritonavir

B. Ha, D. Berger, E. Dejesus, 2010, HIV clinical trials.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

A. Collier, D. Kitch, T. Brown, 2016, The Journal of infectious diseases.

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

P. Sax, E. Daar, D. Kitch, 2012, AIDS.

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

P. Sax, E. Daar, D. Kitch, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz : ACTG Study A 5224 s

P. Sax, E. Daar, D. Kitch, 2011 .

Impact of randomized antiretroviral therapy initiation on glucose metabolism

P. Sax, E. Daar, D. Kitch, 2014, AIDS.

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density

P. Sax, E. Daar, D. Kitch, 2013, AIDS.

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

B. Ha, D. Irlbeck, E. Dejesus, 2010, The open AIDS journal.

Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

R. Redfield, B. Ha, C. Cohen, 2009, AIDS Research and Human Retroviruses.

Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults

D. Kitch, T. Brown, G. McComsey, 2015, HIV clinical trials.

Once-Daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-NaïveSubjects: A 48-Week Pilot Study

R. Redfield, B. Ha, C. Cohen, 2006, HIV clinical trials.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353

P. Sax, D. Haas, E. Acosta, 2019, The Journal of antimicrobial chemotherapy.

Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients

R. Haubrich, D. Richman, C. Kemper, 2010, AIDS.

Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1–Infected Patients With or Without Hepatitis B or C Coinfection

B. Ha, M. Shaefer, B. Wine, 2012, HIV clinical trials.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Lynne Peeples, David Katzenstein, Victoria A Johnson, 2009, The New England journal of medicine.

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.

P. Sax, B. Taiwo, B. Ha, 2020, AIDS research and human retroviruses.

Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Markers of renal disease and function are associated with systemic inflammation in HIV infection

D. Kitch, G. McComsey, K. Melbourne, 2015, HIV medicine.

Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial

P. Sax, E. Daar, D. Kitch, 2014, Open forum infectious diseases.

Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy

C. Petropoulos, B. Ha, B. Young, 2011, Antiviral therapy.

Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial

Linda A. Battalora, B. Ha, B. Young, 2014 .

A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial

B. Ha, T. Hawkins, E. Dejesus, 2010, HIV clinical trials.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir

B. Ha, C. Cohen, J. Horton, 2009, The Journal of antimicrobial chemotherapy.

96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: The SHIELD Trial

B. Ha, T. Hawkins, E. Dejesus, 2011, HIV clinical trials.

Markers of renal disease and function are associated with systemic inflammation in HIV infection

D. Kitch, G. McComsey, K. Melbourne, 2015, HIV medicine.